前Bayer Pharma CEO Dieter Weinand加入AstriVax为主席, 因为该公司开始新一轮乙型肝炎试验。 Former Bayer Pharma CEO Dieter Weinand joins AstriVax as Chair, as the company begins a new hepatitis B trial.

以美国为基地的一家免疫治疗公司AstriVax Serecticistics已任命Bayer Pharma前首席执行官Dieter Weinand为董事会新主席。 AstriVax Therapeutics, a US-based immunotherapy company, has appointed Dieter Weinand, former CEO of Bayer Pharma, as its new Chair of the Board of Directors. Weinand 在制药领域拥有超过 25 年的经验，随着 AstriVax 开始一项针对慢性乙型肝炎治疗药物 AVX70371 的新 1 期试验而加入。 Weinand, with over 25 years in pharmaceuticals, joins as AstriVax begins a new Phase 1 trial for AVX70371, a treatment for chronic hepatitis B. 该公司的Tlaunch-iT技术被视为治疗慢性感染的潜在突破。 The company's Launch-iT technology is seen as a potential breakthrough in treating chronic infections.